Clinical Trial Update: A Study to Investigate the Safety and Efficacy of SAR446523 Injected Subcutaneously in Adult Participants With Relapsed/Refractory Myeloma [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating the safety and efficacy of SAR446523 given by subcutaneous injection in adults with relapsed or refractory multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Or Refractory Multiple Myeloma

Drugs mentioned

• SAR446523

Snippet

Sponsor: Sanofi | Conditions: Plasma Cell Myeloma Refractory | Phase 1 | Status: RECRUITING